Modality
Gene Therapy
MOA
WEE1i
Target
PLK4
Pathway
Epigenetic
Hemophilia A
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
Dec 2020
→ Oct 2028
Phase 1Current
NCT07890561
563 pts·Hemophilia A
2020-12→2028-10·Active
563 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-032.5y awayInterim· Hemophilia A
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Active
Catalysts
Interim
2028-10-03 · 2.5y away
Hemophilia A
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07890561 | Phase 1 | Hemophilia A | Active | 563 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |